The development of complement inhibitors has been growing rapidly over the years, and it has proved to be one of the breakthroughs in various therapeutic areas. These inhibitors act on the dysregulated complement system, a group of proteins that forms an essential part of innate immunity. This system comes into effect only when it is activated by three different types of pathways, i.e., classical, alternative, and lectin pathways.
The scientists' interest in the complement system started in the 19th century, but the successful approval of a complement inhibitor was not until 2007. SOLIRIS (Eculizumab) became the first complement inhibitor approved by the US F...
